Recent Trends in Gene Therapy for Treatment of Diseases, Disorders and Conditions
Keywords:
Gene therapy, Advanced Gene Editing Technologies, Therapeutic Applications, clinical trials, genome, mutation, replication, advanced therapy.Abstract
Utilizing developments in genetic engineering and molecular biology, gene therapy has become a great method for treating illnesses. By adding, deleting, or changing genetic material inside a patient's cells, this treatment seeks to address the underlying causes of illness. Many vectors, including viral and non-viral systems, have been developed recently as a result of advancements in technology, improving the effectiveness and specificity of gene delivery. Gene therapy has been a significant advancement in treatment of various disease, disorders and conditions, but its full potential has yet to be realized in clinical settings. Despite various gene modulation approaches, delivering these to cells and tissues remains a challenge. Nanomedicine has developed innovative platforms, primarily focusing on nanoparticles, to overcome this obstacle. This review focuses on approaches of using such gene mutants, or modifications in genetic materials of organism and this could be used for treatment of various hereditary, acquired diseases, disorders and conditions.
References
1. Arruebo M, Vilaboa N, Sáez-Gutierrez B, Lambea J, Tres A, Valladares M, et al. Assessment of the evolution of cancer treatment therapies. Cancers (Basel). 2011;3:3279–330.
2. Zhang W-W, Li L, Li D, Liu J, Li X, Li W, et al. The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic. Hum Gene Ther. 2018;29:160–79.
3. Amer MH. Gene therapy for cancer: present status and future perspective. Mol Cell Ther. 2014;2:1–19.
4. Nathan J, Shameera R, Palanivel G. Studying molecular signaling in major angiogenic diseases. Mol Cell Biochem. 2022;477:2433–50.
5. Oishi T, Ito M, Koizumi S, Horikawa M, Yamamoto T, Yamagishi S, et al. Efficacy of HSV-TK/GCV system suicide gene therapy using SHED expressing modified HSV-TK against lung cancer brain metastases. Mol Ther Methods Clin Dev. 2022;26:253–65.
6. Martin L, Grzela DP. Nucleic Acid-Based Systems for Regenerative Medicine. Princ Bioinspired Biomim Regen Med. 2025;3:267.
7. Tarach P, Janaszewska A. Recent advances in preclinical research using PAMAM dendrimers for cancer gene therapy. Int J Mol Sci. 2021;22:2912.
8. Bauerschmitz GJ, Barker SD, Hemminki A. Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents. Int J Oncol. 2002;21:1161–74.
9. Gabrilovich DI. INGN 201 (Advexin®): adenoviral p53 gene therapy for cancer. Expert Opin Biol Ther. 2006;6:823–32.
10. Romano G, Micheli P, Pacilio C, Giordano A. Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications. Stem Cells. 2000;18:19–39.
11. Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy comes of age. Science (80- ). 2018;359:eaan4672.
12. Abreu NJ, Waldrop MA. Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy. Pediatr Pulmonol. 2021;56:710–20.
13. Sivamani Y, Hegde S, Bhat AR, Sajal H, Elayaperumal S. Recombinant DNA technology and gene therapy. Biochem Mol Pharmacol Drug Discov. Elsevier; 2024. p. 353–76.
14. Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev Genet. 2007;8:573–87.
15. Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS. Spinal muscular atrophy. Nat Rev Dis Prim. 2022;8:52.
16. Cusin V, Clermont O, Gerard B, Chantereau D, Elion J. Prevalence of SMN1 deletion and duplication in carrier and normal populations: implication for genetic counselling. J Med Genet. 2003;40:e39–e39.
17. Naveed A, Calderon H. Onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J Pediatr Pharmacol Ther. 2021;26:437–44.
18. Pattali R, Mou Y, Li X-J. AAV9 Vector: a Novel modality in gene therapy for spinal muscular atrophy. Gene Ther. 2019;26:287–95.
19. Bowerman M, Becker CG, Yáñez-Muñoz RJ, Ning K, Wood MJA, Gillingwater TH, et al. Therapeutic strategies for spinal muscular atrophy: SMN and beyond. Dis Model Mech. 2017;10:943–54.
20. Matteson J, Wu CH, Mathur D, Tang H, Sciortino S, Feuchtbaum L, et al. California’s experience with SMA newborn screening: A successful path to early intervention. J Neuromuscul Dis. 2022;9:777–85.
21. Kay DM, Stevens CF, Parker A, Saavedra-Matiz CA, Sack V, Chung WK, et al. Implementation of population-based newborn screening reveals low incidence of spinal muscular atrophy. Genet Med. 2020;22:1296–302.
22. Ertl HCJ. Immunogenicity and toxicity of AAV gene therapy. Front Immunol. 2022;13:975803.
23. Towbin JA, Hejtmancik JF, Brink P, Gelb B, Zhu XM, Chamberlain JS, et al. X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation. 1993;87:1854–65.
24. Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev. 2002;82:291–329.
25. Syed DS, Khan MS, Afnan U, Dar MJ, Maqbool T. Muscular Dystrophy: Underlying Cellular and Molecular Mechanisms and Various Nanotherapeutic Approaches for Muscular Dystrophy. Mech Genet Susceptibility Neurol Disord. Springer; 2024. p. 145–97.
26. Gilbert-Barness E. Metabolic cardiomyopathy and conduction system defects in children. Ann Clin Lab Sci. 2004;34:15–34.
27. Darmahkasih AJ, Rybalsky I, Tian C, Shellenbarger KC, Horn PS, Lambert JT, et al. Neurodevelopmental, behavioral, and emotional symptoms common in Duchenne muscular dystrophy. Muscle Nerve. 2020;61:466–74.
28. Brogna C, Moriconi F, Capasso A, Arpaia C, Cicala G, Ricci M, et al. Identification and treatment of neurodevelopmental and mental disorders in boys and adults with Duchenne muscular dystrophy: a cohort study. Arch Dis Child. 2025;
29. Elangkovan N, Dickson G. Gene therapy for Duchenne muscular dystrophy. J Neuromuscul Dis. 2021;8:S303–16.
30. Feng LR, Maguire-Zeiss KA. Gene therapy in Parkinson’s disease: rationale and current status. CNS Drugs. 2010;24:177–92.
31. Huang Q. Genetic study of complex diseases in the post-GWAS era. J Genet Genomics. 2015;42:87–98.
32. Rocca WA. The burden of Parkinson’s disease: a worldwide perspective. Lancet Neurol. 2018;17:928–9.
33. Kovacs GG. Molecular pathology of neurodegenerative diseases: principles and practice. J Clin Pathol. 2019;72:725–35.
34. Kordower JH. In vivo gene delivery of glial cell line–derived neurotrophic factor for Parkinson’s disease. Ann Neurol Off J Am Neurol Assoc Child Neurol Soc. 2003;53:S120–34.
35. Przedborski S, Vila M. MPTP: a review of its mechanisms of neurotoxicity. Clin Neurosci Res. 2001;1:407–18.
36. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, et al. T lymphocyte-directed gene therapy for ADA− SCID: initial trial results after 4 years. Science (80- ). 1995;270:475–80.
37. Husain SR, Han J, Au P, Shannon K, Puri RK. Gene therapy for cancer: regulatory considerations for approval. Cancer Gene Ther. 2015;22:554–63.
38. Oguntibeju OO. Quality of life of people living with HIV and AIDS and antiretroviral therapy. HIV/AIDS-Research Palliat Care. 2012;117–24.
39. Lai Y. CCR5-targeted hematopoietic stem cell gene approaches for HIV disease: current progress and future prospects. Curr Stem Cell Res Ther. 2012;7:310–7.
